This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meijer, E.
Right arrow Articles by Verdonck, L. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meijer, E.
Right arrow Articles by Verdonck, L. F.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, October 2003, p. 647-657, Vol. 16, No. 4
0893-8512/03/$08.00+0     DOI: 10.1128/CMR.16.4.647-657.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants

Ellen Meijer,1* Greet J. Boland,2 and Leo F. Verdonck1

Department of Hematology, University Medical Center,1 Department of Virology, Eijkman-Winkler Institute Utrecht, The Netherlands2

The main risk factors for cytomegalovirus (CMV) disease in recipients of allogeneic stem cell transplants (SCT) are recipient CMV seropositivity and acute graft-versus-host disease. Currently, two antiviral strategies, prophylactic or preemptive antiviral treatment, are used for prevention of CMV disease. Preemptive treatment is most favorable when short-term (14-day) treatment is applied. Several methods are available for monitoring of CMV reactivation. PCR-based CMV DNA detection assays are the most sensitive methods; however, the clinical benefit of this high sensitivity is unclear. Even more, there is lack of clarity whether PCR tests can better be performed with plasma, whole blood, or peripheral blood leukocyte samples. Recovery of a CMV-specific CD8+ cytotoxic-T-lymphocyte (CTL) response is necessary for preventing CMV reactivation and disease. Reconstitution of absolute CMV-specific CTL counts to values above 10 x 106 to 20 x 106 CTLs/liter is associated with protection from CMV disease. In the near future, preemptive therapy might be withheld in patients with CMV reactivation who are shown to have adequate CMV-specific cytotoxic T-cell levels. Antiviral therapy with (val)acyclovir has been studied only as prophylactic treatment for prevention of CMV infection. High-dose oral valacyclovir is more effective than acyclovir when used in addition to preemptive treatment of CMV reactivation with ganciclovir or foscarnet. Three antiviral drugs have been tested for preemptive therapy of CMV reactivation and/or treatment of CMV disease. Although intravenous ganciclovir is considered the drug of choice, foscarnet has similar efficacy and less toxicity, especially hematologic toxicity. Cidofovir has not been tested extensively, but so far the results are disappointing. Oral valganciclovir for preemptive treatment of SCT recipients is currently being studied. In addition to antiviral therapy, adoptive immunotherapy with CMV-specific cytotoxic T cells as prophylactic or preemptive therapy is a very elegant strategy; however, generation of these cells is expensive and time-consuming, and therefore the therapy is not available at every transplantation center. Magnetic selection of CMV-specific CD8+ T cells from peripheral blood by using HLA class I-peptide tetramers may be very promising, making this strategy more accessible.

* Corresponding author. Mailing address: University Medical Center Utrecht, Department of Hematology/G03.647, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. Phone: 31302507230. Fax: 31302511893. E-mail: emeijer{at}digd.azu.nl.

Clinical Microbiology Reviews, October 2003, p. 647-657, Vol. 16, No. 4
0893-8512/03/$08.00+0     DOI: 10.1128/CMR.16.4.647-657.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Michelin, B. D. A., Hadzisejdic, I., Bozic, M., Grahovac, M., Hess, M., Grahovac, B., Marth, E., Kessler, H. H. (2008). Detection of Cytomegalovirus (CMV) DNA in EDTA Whole-Blood Samples: Evaluation of the Quantitative artus CMV LightCycler PCR Kit in Conjunction with Automated Sample Preparation. J. Clin. Microbiol. 46: 1241-1245 [Abstract] [Full Text]  
  • Marty, F. M., Bryar, J., Browne, S. K., Schwarzberg, T., Ho, V. T., Bassett, I. V., Koreth, J., Alyea, E. P., Soiffer, R. J., Cutler, C. S., Antin, J. H., Baden, L. R. (2007). Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 110: 490-500 [Abstract] [Full Text]  
  • Swan, S. K., Smith, W. B., Marbury, T. C., Schumacher, M., Dougherty, C., Mico, B. A., Villano, S. A. (2007). Pharmacokinetics of Maribavir, a Novel Oral Anticytomegalovirus Agent, in Subjects With Varying Degrees of Renal Impairment. J Clin Pharmacol 47: 209-217 [Abstract] [Full Text]  
  • Einsele, H., Reusser, P., Bornhauser, M., Kalhs, P., Ehninger, G., Hebart, H., Chalandon, Y., Kroger, N., Hertenstein, B., Rohde, F., for the EBMT Working Group on Infectious Disease, (2006). Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 107: 3002-3008 [Abstract] [Full Text]  
  • Gosselin, J., Borgeat, P., Flamand, L. (2005). Leukotriene B4 Protects Latently Infected Mice against Murine Cytomegalovirus Reactivation following Allogeneic Transplantation. J. Immunol. 174: 1587-1593 [Abstract] [Full Text]  
  • Elkington, R., Khanna, R. (2005). Cross-recognition of human alloantigen by cytomegalovirus glycoprotein-specific CD4+ cytotoxic T lymphocytes: implications for graft-versus-host disease. Blood 105: 1362-1364 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»